Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia

Abstract Background Treatment‐free remission (TFR) has become the main target for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKI) dose optimization is crucial in managing adverse events, and improving adherence in clinical practice. In persons achieving a deep molecular response (DM...

Full description

Bibliographic Details
Main Authors: Yilin Chen, Na Xu, Yunfan Yang, Zhenfang Liu, Mengxing Xue, Li Meng, Qun He, Chunyan Chen, Qingshu Zeng, Huanling Zhu, Xin Du, Jing Zou, Wenjun He, Jingming Guo, Suning Chen, Guolin Yuan, Hui Wu, Mei Hong, Fanjun Cheng, Bingcheng Liu, Yanli Zhang, Weiming Li
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
chronic myeloid leukemia
mental health
quality‐of‐life
TKI dose reduction
treatment‐free remission
Online Access:https://doi.org/10.1002/cam4.6296

Internet

https://doi.org/10.1002/cam4.6296

Similar Items